The class of CaMK1γ inhibitors encompasses a range of chemical compounds designed to mitigate the activity of the Calcium/Calmodulin-Dependent Protein Kinase I gamma (CaMK1γ). These compounds primarily function through two broad mechanisms: by targeting the calcium/calmodulin binding sites, or by affecting the kinase domain. Compounds such as KN-93 and KN-62 specifically target the calcium/calmodulin binding site, thereby the kinase from becoming activated upon calcium influx and calmodulin binding. STO-609 and A-484954, on the other hand, exert their effects on the kinase domain. They function either by impairing ATP utilization or acting as competitive inhibitors at the ATP binding site, which is a key locus for the kinase's activity.
Other inhibitors like H-89 and KT 5720, originally designed for Protein Kinase A (PKA), exhibit cross-reactivity with CaMK1γ due to similarities in the kinase domains of PKA and CaMK1γ. Further, some inhibitors like SB 203580 and Wortmannin primarily target other kinases or pathways but show activity against CaMK1γ as off-target effects. It should be noted that the specificity of each inhibitor can vary, and the off-target effects are an important consideration in their application for pathway-specific inhibition. Overall, this group of chemicals offers a toolbox for modulating CaMK1γ activity in a variety of cellular contexts, albeit with varying degrees of specificity and mechanism of action.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
KN-93 inhibits CaMK1γ by blocking calcium/calmodulin binding. It has high specificity for CaMK1 isoforms. | ||||||
STO-609 | 52029-86-4 | sc-507444 | 5 mg | $140.00 | ||
This compound blocks the kinase domain, impairing ATP utilization and thereby inhibits CaMK1γ activity. | ||||||
A 484954 | 142557-61-7 | sc-479613 | 10 mg | $175.00 | ||
Inhibits CaMK1γ through competitive inhibition at the ATP binding site. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $90.00 $317.00 | 17 | |
Inhibits CaMK1γ by blocking calcium and calmodulin binding sites. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Targets the ATP-binding site to inhibit CaMK1γ activity. | ||||||
KT 5720 | 108068-98-0 | sc-3538 sc-3538A sc-3538B | 50 µg 100 µg 500 µg | $138.00 $220.00 $972.00 | 47 | |
A PKA inhibitor that also has cross-reactivity to inhibit CaMK1γ. | ||||||
KN-62 | 127191-97-3 | sc-3560 | 1 mg | $136.00 | 20 | |
Blocks calcium/calmodulin binding sites on CaMK1γ. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Although primarily a p38 MAPK inhibitor, it shows inhibition of CaMK1γ. | ||||||
Trifluoperazine Dihydrochloride | 440-17-5 | sc-201498 sc-201498A | 1 g 5 g | $57.00 $101.00 | 9 | |
An antipsychotic that has been observed to inhibit CaMK1γ by blocking calmodulin binding. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Inhibits phosphoinositide 3-kinases but can also impair CaMK1γ through general kinase inhibition. | ||||||